Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib

NCT01298323 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01298323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01298323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
February 25, 2011
Completion date
March 13, 2025
Enrollment
205 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic medullary thyroid cancer, medullary thyroid cancer